Carney and Poilievre tackle tough questions on Radio-Canada show
The CBC Poll Tracker indicates that Carney's Liberals are leading in Quebec with 42.4% of the popular vote, with the Bloc Québécois and the Poilievre's Conservatives close behind at 23.5% and 23.2%, respectively. This is despite heavy criticism of Carney, who has made several Quebec-related mistakes during his campaign run. Carney was candid about his French language skills and cultural knowledge of Quebec, admitting, "My French is not perfect... I make gaffes."
Carney, who served as the governor of the Central Bank of Canada during the 2008 recession, highlighted his collaboration with the then-Quebec premier Jean Charest to navigate through the economic downturn. He also addressed the topic of potential future pipelines in Quebec, emphasizing that any such project would require social acceptability and noting that Quebecers use 355,000 barrels of oil per day, mostly imported from the United States.
Conservative leader Poilievre faced scrutiny over the perception that he shares similarities with former U.S. President Donald Trump. Responding to a playful question about whether he is a "mini-Trump," Poilievre humorously referred to his weight and underscored his modest upbringing, contrasting it with Trump's inherited wealth. He stated, "I have a completely different story from Donald Trump."
On the topic of negotiation skills, particularly with the U.S. president, Poilievre expressed confidence, saying, "It's certain that if I can face Guy A. Lepage, I can face Donald Trump," to which Lepage retorted, "Yes, but I don't have tariffs."
The leaders are preparing for the upcoming debates in both French and English at the Maison Radio-Canada in Montreal, scheduled for this Wednesday and Thursday.
Related articles
Aspen Aerogels stock hits 52-week low at $6.59 amid market challenges
Macquarie Reiterates Outperform Rating on Nickel Industries Ltd
Take Five: T is for tariffs
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Grieg Seafood sells Finnmark, Canada units to Mitsubishi's Cermaq for $993 million
COPENHAGEN (Reuters) -Norwegian salmon farming group Grieg Seafood said on Thursday it had agreed to sell its operations in Norway's Finnmark and in Canada to Mitsubishi unit Cermaq for 10.2 billion crowns ($993 million). "The sale allows Grieg Seafood to concentrate its focus on the Rogaland region in Western Norway," it said in a statement. Grieg Seafood said it expects to close the deal in the fourth quarter. ($1 = 10.2705 Norwegian crowns) Sign in to access your portfolio
Fox News
3 minutes ago
- Fox News
Meet The Parents
AOC brings a communist pirate home to meet the parents, and now the entire house is divided. Learn more about your ad choices. Visit FOX News Radio
Associated Press
33 minutes ago
- Associated Press
Lobe Sciences Ltd. Announces Debt Settlement
VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that it has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for legal services previously provided to the Company. In satisfaction of this obligation, Lobe has issued 546,206 common shares of the Company to Gibbson Law P.C. at a deemed price of CAD$0.02123 per share. The shares were issued on May 13, 2025, and are subject to applicable regulatory hold periods under Canadian securities laws. About Lobe Sciences - Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) is a biopharmaceutical company focused on developing innovative therapies for rare and underserved conditions. Through its wholly owned subsidiary, Altemia, Inc., and its majority-owned subsidiary, Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented lipid-based platform for treating Sickle Cell Disease and a novel oral analog of psilocin-Conjugated Psilocin™-targeted at Chronic Cluster Headache and other neurological disorders. These programs address significant unmet medical needs with the potential to improve outcomes in both hematologic and neuropsychiatric patient populations. For further information: Dr. Fred D. Sancilio, CEO Lobe Sciences Ltd. Investor and Media [email protected] Phone: +1 (949) 505-5623 Cautionary Statement Regarding 'Forward-Looking' Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company's intention to raise funds for clinical trials, the innovativeness of Conjugated Psilocin™. the anticipated focus and timing or efficiency of the Company's research and development activities; the potential for the Company's products to meet unmet medical needs, the anticipated use of proceeds from the offering, the intended development plans for Cynaptec™, the intention of Lobe Sciences to provide certain services to Cynaptec, the potential exercise of the option and intended use of proceeds therefrom and the potential ability to raise funds for clinical development are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as 'intends' or 'anticipates', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'should' or 'would' or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company's planned activities will be able to create shareholder value and address serious unmet medical needs; the Company will continue to pursue its planned research and development activities, and that the Company will be able to raise funds among others. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company's planned activities will be unable to create shareholder value or address the targeted unmet medical needs; the Company is unable to obtain the desired results from its current research and development activities; and the Company is unable to raise funds or to do so on the timelines anticipated. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE. SOURCE: Lobe Sciences Ltd. press release
